DeCure's autonomous Dermatology AI scientist is researching a drug-repurposing hypothesis for hemangioma of subcutaneous tissue — screening already-approved drugs against its 20-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHemangioma of subcutaneous tissue maps to a 20-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hemangioma of subcutaneous tissue is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
fragile histidine triad diadenosine triphosphatase (FHIT) — FHIT is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet frudrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1FIT · 1.85 Å · ligand beta-D-fructofuranose (FRU). Experimental structure, not a prediction.
What the evidence adds up to
Verrucous hemangioma is a rare vascular lesion that extends into the subcutaneous tissue, with a pseudoinfiltrative pattern of capillary lobules merging with adipose cells. In a 1995 series of 10 patients aged 6 to 44 years, all lesions were on the lower extremities, and among six cases with follow-up, two recurred. The authors attributed recurrence to underestimation of the lesion’s lateral and deep extent, which often exceeds the visible warty surface, leading to inadequate excision. Histologically, the endothelial cells were flat and showed strong CD34 staining but variable factor VIII reactivity; all vascular channels were surrounded by actin-positive pericytes. The overlying warty change was reactive, not caused by human papillomavirus.
A 2018 review confirms that verrucous hemangioma reaches the subcutaneous tissue, distinguishing it from angiokeratoma circumscriptum neviforme, where vascular changes are confined to the papillary dermis. The clinical presentations are nearly indistinguishable, so histopathology is essential for correct diagnosis. No treatment data are provided in either the 1995 or 2018 paper.
A separate 2016 case report describes a deep hemangioma in the periorbital region with no overlying skin changes that showed excellent response to intralesional steroids, with no reported side effects. This is a single case, not a controlled trial, and the lesion is not specified as verrucous hemangioma. The report notes that intralesional steroids are usually not recommended in the periocular region due to risks of eyelid necrosis and central retinal vein occlusion.
No controlled trials exist for verrucous hemangioma treatment. The evidence is limited to small case series and single reports. What is missing is prospective data on recurrence rates after standard excision, any randomised comparison of treatment modalities, and a clear definition of which subcutaneous hemangiomas require intervention versus observation.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Surgical Pathology · 1995 · 21 citations
Verrucous Hemangioma
AbstractVerrucous hemangioma is an uncommon variant of cutaneous hemangioma, showing characteristic clinicopathologic features. Since its formal characterization in 1967, little has been written on this entity. This report describes 10 cases to draw wider attention to this distinct hemangioma. The patients, 5 males and 5 females, were aged 6-44 years at presentation. The lesions were usually noted at birth as flat or dome-shaped reddish or bluish lesions that enlarged slowly and became verrucous. All 10 cases were located in the lower extremities. Among the six cases with follow-up information, two have recurred. Histologically, beneath the warty epidermal surface, haphazardly distributed in the dermis were vascular spaces often of cavernous size, merging into capillaries in the subcutis. In the subcutaneous tissue, the lobules of capillaries com monly merged with the adipose cells in a pseudoinfiltrative pattern. The endothelial cells were flat and nondescript, and showed variable immunoreactivity for factor VIII related antigen but showed strong staining with CD34. All the vascular channels were surrounded by complete rims of muscle-specific actin-positive pericytes. The overlying epidermis lacked evidence of human papillomavirus infection either by immunohisto chemical studies or ultrastructural examination. Thus the warty change represented a reactive phenomenon rather than a result of human papillomavirus infection. Since the lateral and deep extent of the vascular proliferation is often greater than that of the exophytic epidermal component in verrucous hemangioma, the size of the lesion is often underestimated, leading to inadequate excision and recurrence. Awareness of this entity and obtaining a complete clinical history should permit recognition of the lesion as a vascular lesion and not a primary epidermal or melanocytic lesion. Int J Surg Pathol 2(3):171-176, 1995
Anais Brasileiros de Dermatologia · 2018 · 16 citations · open access
Verrucous hemangioma and histopathological differential diagnosis with angiokeratoma circumscriptum neviforme
AbstractVerrucous hemangioma is a rare vascular skin disorder with an immune profile similar to vascular neoplasms, but with behavior and evolution of vascular malformations. Its main differential diagnosis is angiokeratoma circumscriptum neviforme, with an almost indistinguishable clinical presentation because both diseases appear as erythematous patches that evolve to violaceous plaques, becoming scaly and even verrucous, most commonly affecting the lower limbs. Histopathology is crucial for the correct diagnosis: while in angiokeratoma the vascular alterations are limited to the papillary dermis, verrucous hemangioma extends deep into the dermis, reaching the subcutaneous tissue.
Journal of Pakistan Association of Dermatologists · 2016 · 0 citations · open access
A rare case of deep hemangioma presenting as a periorbital swelling and its excellent response to intralesional steroids
AbstractA hemangioma is a benign and usually self-involuting tumor of the endothelial cells of blood vessels, and is characterized by an increased number of normal or abnormal vessels. It usually appears in the first few weeks of life and grows most rapidly over the first six months. Usually, growth is complete and involution has commenced by twelve months. Half of all infantile hemangiomas involute by age five, 70% by age seven, and most of the remainder by age twelve. In more severe cases hemangiomas may leave residual tissue damage. The dermatologic indications for intervention in a case of hemangioma include maceration and erosion of the epidermis, infection, and cosmetic disfigurement. The treatment options include corticosteroids (oral), interferon, vincristine, propranolol, pulsed dye laser and surgery. The intralesional steroids are usually not recommended in the periocular region because of side effects like eyelid necrosis and central retinal vein occlusion. Here we report the case of a deep hemangioma in periorbital region with no overlying skin changes and its excellent response to intralesional steroids with no side effects.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
